On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug Administration.

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

The US Food and Drug Administration (FDA ... About one in 300 people worldwide are affected by schizophrenia, but for decades treatment options have been both static and limited.

Causes psychosis as a side effect of a drug, like hallucinogens or certain prescription medications If you or a loved one are experiencing signs of schizophrenia, seeing a healthcare provider ...

The current treatment landscape for schizophrenia is dominated by ... Myers Squibb’s (BMS’) KarXT as potential US Food and Drug Administration (FDA) approval looms. The Prescription Drug ...